ArticleNature communications2021
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- TRIM24 in Human Cancers: A Dual-Function Oncoprotein, Regulatory Mechanisms, and Emerging Therapeutic Strategies.International journal of cancer · 2026Review
- TRIM Protein Superfamily in Breast Cancer: Yin and Yang.Biochemical genetics · 2026Review
- The Regulation of p53 by Ubiquitination and Implications for Therapeutic Targeting in Colorectal Cancer.Genes · 2026Article
- A Histone Deacetylase Activity Model for the Discovery and Validation of Sepsis Biomarkers.Endocrine, metabolic & immune disorders drug targets · 2026Article
- TRIM proteins as emerging regulators of immune pathways: potential therapeutic targets in immune-related disorders.Frontiers in immunology · 2026Review
- Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer.NPJ breast cancer · 2025Article
- The latest progress of personalized drug screening and therapy research for common clinical tumors through the PDX model platform.Journal of pharmaceutical analysis · 2025Review
- Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis.Molecular oncology · 2025Article
- TRIM24 as a therapeutic target in endocrine treatment-resistant breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- α-Cyperone affects the development and chemosensitivity of breast cancer by modulating TRIM24.In vitro cellular & developmental biology. Animal · 2025Article
- Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes.Nature communications · 2025Article
- NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.Nature communications · 2024Article
- Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research.International journal of molecular sciences · 2024Review
- BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.Science translational medicine · 2024Article
- The tripartite motif-containing 24 is a multifunctional player in human cancer.Cell & bioscience · 2024Review
- A comprehensive overview of metaplastic breast cancer: Features and treatments.Cancer science · 2024Review
- TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA-PKcs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer.Cancer medicine · 2024Review
- Retinoblastoma-associated protein is important for TRIM24-mediated activation of the mTOR signaling pathway through DUSP2 action in prostate cancer.Cell death and differentiation · 2024Article
- Breast cancer histopathology, classification and clinical management: Current perspectives.Bioinformation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 1 institution in 1 country.
Vrutant V Shah *Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5342-6513
Aundrietta D Duncan *The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1094-4844
Shiming Jiang *The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sabrina A StrattonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5408-8242
Kendra L AlltonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4204-0807
Clinton YamThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abhinav JainThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick M KrauseDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1611-9068
Yue LuThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shirong CaiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yizheng TuThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xinhui ZhouThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaomei ZhangThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0964-8922
Yan JiangThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher L CarrollThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhijun KangThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bin LiuThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun ShenThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mihai GageaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2399-1375
Sebastian M ManuThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lei HuoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael GilcreaseThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reid T PowellCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M College of Medicine, Houston, TX, USA.
Lei GuoCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M College of Medicine, Houston, TX, USA.
Clifford StephanCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M College of Medicine, Houston, TX, USA.
Peter J DaviesCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M College of Medicine, Houston, TX, USA.
Jan Parker-ThornburgDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4464-8744
Guillermina LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8985-4886
Richard R BehringerDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Helen Piwnica-WormsThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4210-6738
Jeffrey T ChangUniversity of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, University of Texas, Houston, TX, USA. jeffrey.t.chang@uth.tmc.edu.ORCID 0000-0002-4578-5636
Stacy L MoulderThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. smoulder@mdanderson.org.
Michelle Craig BartonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. bartonsh@ohsu.edu.ORCID 0000-0002-4042-1374
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MThe roles of TRIM24 in breast cancerR01CA214871 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOZANO, GUILLERMINA · 2017 to 2021
$2.0MInstituting innovative CRISPR/Cas9 technology at an NCI Comprehensive Cancer Center transgenic facilityR50CA211121 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PARKER-THORNBURG, JAN · 2017 to 2021
$1.2MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA214871NCI NIH HHS R50 CA211121
Abstract
Conditional overexpression of histone reader Tripartite motif containing protein 24 (TRIM24) in mouse mammary epithelia (Trim24
Indexed as
AnimalsBreastCarcinosarcomaCarrier ProteinsClinical Trials as TopicFemaleGene Expression Regulation, NeoplasticHumansMammary Glands, AnimalMammary Neoplasms, ExperimentalMiceMice, TransgenicNuclear ProteinsPrimary Cell CultureProto-Oncogene Proteins c-metRNA-SeqCarrier ProteinsHGFR protein, mouseMET protein, humanNuclear ProteinsProto-Oncogene Proteins c-mettranscriptional intermediary factor 1Transcription FactorsTRIM24 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.